Real-World Data Sharpen the Case for Safe and Effective Psychedelic Therapies
New psychedelic studies from October show 5-year safety data from esketamine, the importance of set & setting, and microdosing null-results.
Research
New Psychedelic Studies Advance Clinical Applications
New psychedelic studies from September show psilocybin for addiction, LSD for anxiety, and group therapy for burnout, guiding clinical and policy integration.
Economic, Clinical, and Real-world Insights
The latest research on psychedelic-assisted therapies in August provides critical insights into economic feasibility, implementation models, and clinical effectiveness across diverse patient groups.
Cross-Diagnostic Potential of Psychedelics
New psychedelic studies highlight cross-indication applicability of MDMA-assisted therapy, risks with naturalistic use, and potential life-extending effects of psilocybin.
How New Psychedelic Studies Inform Clinical Implementation
New psychedelic studies highlight durable effects of psilocybin therapy, Delphi consensus, and pivotal Phase II and III trials.
Economic Impacts, Therapeutic Advances, and Emotional Benefits
New psychedelic studies highlight ketamine’s economic benefits, psilocybin’s spiritual impact, and DMT’s potential therapeutic uses.
Rapid and Sustained Psychedelic Treatments Show Promise in Recent Clinical Trials
Recent psychedelic research provides crucial insights for drug developers, advocates, and policy leaders, demonstrating the practical potential of psychedelic treatments to transform mental health care delivery.
